Table 3 Associations between CD73 expression and clinical and pathological variables in each arm of the AZURE trial.
Standard treatment | Standard treatment + zoledronate | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
End point | # at risk | # Events | HR | HR: 95% CI | P-value | # at risk | # Events | HR | HR: 95% CI | P-value | |
OS | Unadjusted Adjusted | 207 207 | 66 66 | 1.87 1.53 | 1.06–3.29 0.85-2.77 | 0.03 0.15 | 222 222 | 61 61 | 1.06 0.833 | 0.572 − 1.96 0.444 − 1.56 | 0.86 0.57 |
DFS | Unadjusted Adjusted | 207 207 | 81 81 | 1.66 1.35 | 0.982 − 2.80 0.78-2.34 | 0.06 0.28 | 222 222 | 79 79 | 0.885 1.35 | 0.504 − 1.55 0.76-2.41 | 0.67 0.30 |
Skeletal-first distant recurrence# | Unadjusted Adjusted | 207 207 | 33 33 | 2.23 2.44 | 1.04–4.81 1.08–5.49 | 0.04 0.03 | 222 222 | 20 20 | 0.945 1.05 | 0.316 − 2.83 0.34-3.29 | 0.92 0.93 |
Bone metastasis at any time | Unadjusted Adjusted | 207 207 | 51 51 | 1.86 1.91 | 0.97-3.55 0.97-3.75 | 0.062 0.06 | 222 222 | 31 31 | 0.717 0.694 | 0.275 − 1.87 0.260 − 1.85 | 0.50 0.46 |
Distant recurrence including skeletal | Unadjusted Adjusted | 207 207 | 60 60 | 1.77 1.56 | 0.97-3.21 0.84 − 2.90 | 0.06 0.16 | 222 222 | 52 52 | 0.872 0.694 | 0.438 − 1.74 0.344 − 1.41 | 0.70 0.31 |
Non-skeletal first distant recurrence## | Unadjusted Adjusted | 207 207 | 36 36 | 1.74 1.25 | 0.791 − 3.82 0.55–2.84 | 0.17 0.60 | 222 222 | 38 38 | 0.850 0.606 | 0.374 − 1.93 0.264 − 1.39 | 0.70 0.24 |
